Safety and Pharmacokinetics of Islatravir in Individuals with Severe Renal Insufficiency-Reference-Cited by-同舟云学术

Safety and Pharmacokinetics of Islatravir in Individuals with Severe Renal Insufficiency

Published:2022-12-20 Issue:12 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Matthews Randolph P.¹^ORCID,Cao Youfang¹,Patel Munjal¹,Weissler Vanessa L.¹,Bhattacharyya Arinjita¹,De Lepeleire Inge²,Last Stefanie³,Rondon Juan C.⁴,Vargo Ryan¹,Stoch S. Aubrey¹,Iwamoto Marian¹

Affiliation:

1. Merck & Co., Inc., Rahway, New Jersey, USA

2. MSD (Europe) Inc., Brussels, Belgium

3. Charité Research Organization, Berlin, Germany

4. Clinical Pharmacology of Miami, Miami, Florida, USA

Abstract

Islatravir (MK-8591) is a high-potency reverse transcriptase translocation inhibitor in development for the treatment of HIV-1 infection. Data from preclinical and clinical studies suggest that ~30% to 60% of islatravir is excreted renally and that islatravir is not a substrate of renal transporters.

Funder

Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00931-22

Reference29 articles.

1. 4′-Ethynyl-2-fluoro-2′-deoxyadenosine, MK-8591

2. 4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) Inhibits HIV-1 Reverse Transcriptase with Multiple Mechanisms

3. Structural basis of HIV inhibition by translocation-defective RT inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA)

4. Response of Simian Immunodeficiency Virus to the Novel Nucleoside Reverse Transcriptase Inhibitor 4′-Ethynyl-2-Fluoro-2′-DeoxyadenosineIn VitroandIn Vivo

5. Islatravir for the treatment and prevention of infection with the human immunodeficiency virus type 1

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intracellular islatravir-triphosphate half-life supports extended dosing intervals;Antimicrobial Agents and Chemotherapy;2024-09-04

2. Thorough QT/QTc study to evaluate the effect of a single supratherapeutic dose of islatravir on QTc interval prolongation in healthy adults;Antimicrobial Agents and Chemotherapy;2024-08-07

3. Islatravir: evaluation of clinical development for HIV and HBV;Expert Opinion on Investigational Drugs;2024-01-26

4. Remimazolam tosylate's long-term sedative properties in ICU patients on mechanical ventilation: effectiveness and safety;European Journal of Medical Research;2023-10-21